Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Open-label Study of SNX281 Given as Monotherapy and in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid Tumors and Lymphoma

NCT04609579 is registered in ClinicalTrials.gov with Stingthera, Inc. as lead sponsor.

NCT NCT04609579
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04609579 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Open-label Study of SNX281 Given as Monotherapy and in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid Tumors and Lymphoma
Lead sponsor
Stingthera, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
November 18, 2020
Completion date
January 6, 2024
Enrollment
27 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

advanced lymphoma, advanced solid tumor